I. F. Tannock Et Al. , "Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial," LANCET ONCOLOGY , vol.14, no.8, pp.760-768, 2013
Tannock, I. F. Et Al. 2013. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. LANCET ONCOLOGY , vol.14, no.8 , 760-768.
Tannock, I. F., Fizazi, K., Ivanov, S., Karlsson, C. T., Flechon, A., Skoneczna, I., ... Orlandi, F.(2013). Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. LANCET ONCOLOGY , vol.14, no.8, 760-768.
Tannock, Ian Et Al. "Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial," LANCET ONCOLOGY , vol.14, no.8, 760-768, 2013
Tannock, Ian F. Et Al. "Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial." LANCET ONCOLOGY , vol.14, no.8, pp.760-768, 2013
Tannock, I. F. Et Al. (2013) . "Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial." LANCET ONCOLOGY , vol.14, no.8, pp.760-768.
@article{article, author={Ian F. Tannock Et Al. }, title={Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial}, journal={LANCET ONCOLOGY}, year=2013, pages={760-768} }